Correlation between annual change in health status and computer tomography derived lung density in subjects with α1-antitrypsin deficiency

Thorax

Volumn 58, Issue 12, 2003, Pages 1027-1030

  Stolk, J ^a   Ng, W H ^a   Bakker, M E ^a   Reiber, J H C ^a   Rabe, K F ^a   Putter, H ^a   Stoel, B C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DIAGNOSTIC VALUE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; IMAGE ANALYSIS; INSPIRATORY CAPACITY; LUNG EMPHYSEMA; LUNG VOLUME; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0347291903     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.12.1027     Document Type: Article

References (17)

1. Eriksson S. Pulmonary emphysema and alpha-1-antitrypsin deficiency. Acta Med Scand 1964;175:197-205.
2. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (Pi ZZ). Eur Respir J 1999;13:247-51.
3. Black LF, Kueppers F. Alpha-1-antitrypsin deficiency in non-smokers. Am Rev Respir Dis 1978;117:421-8.
4. Dirksen A, Dijkman JH, Madsen F, et al. A randomised clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-72.
5. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398-404.
6. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
7. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
8. Stockley RA. Alpha-1-antitrypsin deficiency: what next? Thorax 2001;55:614-8.
9. Gould GA, MacNee WA, McLean A, et al. CT measurements of lung density in life can quantitate distal airspace enlargements: an essential defining feature of human emphysema. Am Rev Respir Dis 1988;137:380-92.
10. Gevenois PA, De Vuyst P, de Maertelaer V, et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996;154:187-92.
11. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-9.
12. European Respiratory Society. Standardized lung function testing. Lung volumes and forced ventilatory flows: 1993 update. Eur Respir J 1993;6(Suppl 16):5-40.
13. Cotes JE, Chinn DJ, Quanjer, et al. Standardization of the measurement of transfer factor (diffusion capacity). Eur Respir J 1993;48:119-24.
14. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
15. Stoel BC, Vrooman HA, Stolk J, et al. Sources of error in lung densitometry with CT. Invest Radiol 1999;34:303-9.
16. Spencer S, Calverley PMA, Burge PS, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-8.
17. Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ 1978;1:1645-8.